Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $53.1 million.

  • Insight Molecular Diagnostics' Total Liabilities fell 1218.41% to $53.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.1 million, marking a year-over-year decrease of 1218.41%. This contributed to the annual value of $47.4 million for FY2024, which is 394.13% down from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Total Liabilities stood at $53.1 million for Q3 2025, which was down 1218.41% from $49.4 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year Total Liabilities high stood at $94.3 million for Q4 2021, and its period low was $22.7 million during Q1 2021.
  • Over the past 5 years, Insight Molecular Diagnostics' median Total Liabilities value was $53.1 million (recorded in 2025), while the average stood at $57.7 million.
  • In the last 5 years, Insight Molecular Diagnostics' Total Liabilities skyrocketed by 33009.66% in 2021 and then crashed by 4814.81% in 2023.
  • Over the past 5 years, Insight Molecular Diagnostics' Total Liabilities (Quarter) stood at $94.3 million in 2021, then tumbled by 35.88% to $60.5 million in 2022, then decreased by 18.51% to $49.3 million in 2023, then decreased by 3.94% to $47.4 million in 2024, then grew by 12.2% to $53.1 million in 2025.
  • Its Total Liabilities stands at $53.1 million for Q3 2025, versus $49.4 million for Q2 2025 and $50.1 million for Q1 2025.